New York is currently home to 4456 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Technology-based Psychosocial Intervention to Support Social Engagement and Well-being in Older Adults With HIV
Recruiting
Older people with HIV (OPH) often live with significant mental health challenges such as social isolation, loneliness, and depression. The objectives of this study are to develop and test the usability and feasibility of a technology-based psychosocial intervention program designed to: enhance social engagement and support; facilitate resource access and education; reduce loneliness; and improve well-being among older adults with HIV who are long-term survivors (diagnosed with HIV ≥ 20 years). T... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: HIV Diagnosis
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Recruiting
This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Icahn School of Medicine at Mount Sinai (ISMMS) - The Blavatnik Family-Chelsea Medical Center, New York, New York
Conditions: Mesothelin-expressing Advanced Cancers
Reducing Obesity Using Social Ties Program
Recruiting
This trial aims to test the feasibility and acceptability of addressing interpersonal barriers to weight-related behavior change. Specifically, the study will test if, by including up to two friends, family members, or co-workers in a lifestyle intervention for weight loss, the person enrolled in the study loses more weight than someone whose friends, family members, or co-workers were not invited to participate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Obesity
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
Recruiting
The goal of this clinical trial is to to learn about different combinations of immunotherapy in patients with colorectal cancer whose cancer has spread to their liver and are planning to have surgery to remove tumor metastases from their liver. The main questions it aims to answer are: * whether these combinations of immunotherapy change the tumor microenvironment in the liver * whether these combinations of immunotherapy are safe and effective when used in colorectal cancer with liver metastas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York, New York
Conditions: Colorectal Cancer Metastatic, Liver Metastases, Colorectal Cancer
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
Recruiting
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: GSK Investigational Site, Brooklyn, New York
Conditions: Asthma
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Recruiting
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Memorial Sloan-Kettering Cancer Center (Mskcc) - New York, New York, New York
Conditions: Advanced Solid Tumor
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Recruiting
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: Metastatic Breast Cancer
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Recruiting
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or D... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/04/2025
Locations: Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities), Commack, New York
Conditions: Non Small Cell Lung Cancer, Metastatic, Recurrent
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
Recruiting
Background: Antiretroviral therapy (ART) can suppress HIV to undetectable levels in people, but the virus rebounds quickly if the drug treatment is stopped; this is because HIV can remain dormant in a pool of blood cells called the persistent viral reservoir (PVR). Yet lifelong ART is expensive and can lead to serious side effects over the long term. Some drugs may be more effective at reducing the PVR. Objective: To see if 2 study drugs (3BNC117-LS and 10-1074-LS) are safe and if they can lo... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/04/2025
Locations: The Rockefeller University, New York, New York
Conditions: HIV-1
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Recruiting
This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. In addition, an open-label exploratory substudy will explore the safety and efficacy of giredestrant in combination wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Early Breast Cancer
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning
Recruiting
This trial tests whether Planning for Your Advance Care Needs (PLAN) intervention works to enhance Latino patients' understanding of and engagement in advanced care planning. The PLAN intervention may be an effective method to help people with cancer plan for and talk about advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
Recruiting
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Montefiore Medical Center-Einstein Campus, Bronx, New York
Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma